About Us

Our Team: Committed to moving the field of microbiome therapeutics forward

  • Joe Trebley, Ph.D

    Founder & Chief Executive Officer

    Dr. Trebley is Co-founder and CEO of Scioto Biosciences and Monon Bioventures.

    Read More
  • Jim Schulz, CPA

    Founder and Chief Financial Officer

    Mr. Schulz is a serial entrepreneur with over 20 years of financial experience working with public accounting firms, Fortune 500 companies and small start-up companies.

    Read More
  • Mark Heiman, Ph.D

    Chief Science Officer

    Mark L. Heiman, Ph.D. has 20+ years at Eli Lilly & Co where he served as researcher and CSO of obesity drug discovery. 

    Read More
  • Kevin Meyer

    Chief Operating Officer

    Kevin Meyer has over 10 years of experience in the life sciences industry, having invented, patented, and commercialized a diverse portfolio of technologies.

    Read More
  • Sanjeev Ahuja, MD, FACP

    Chief Medical Officer

    Sanjeev joins Scioto after being the Chief Medical Officer at several companies, including start-ups.

    Read More
  • Gail E. Besner, M.D.

    Gail E. Besner, M.D.

    As a surgeon and scientist, Gail E. Besner, M.D., joined Nationwide Children’s Hospital and The Ohio State University in 1991 upon completion of her pediatric surgical training.

    Read More
  • Steve Goodman, Ph.D

    Scientific Founder

    Since 2012, Dr. Goodman has been the  principal investigator in the Center for Microbial Pathogenesis.

    Read More
  • Michael Bailey, Ph.D.

    Scientific Founder

    Studies in Dr. Bailey's laboratory focus on determining the impact that the intestinal microbiota have on the local mucosal immune system, and on immune reactivity at systemic sites, particularly during periods of psychological stress.

    Read More
  • Lauren Bakaletz, Ph.D.

    Scientific Founder

    Lauren O. Bakaletz, Ph.D. is a Professor of both Pediatrics and Otolaryngology and serves as Director of the Center for Microbial Pathogenesis at The Research Institute at Nationwide Children’s Hospital in Columbus, OH.

    Read More

Revolutionizing Therapeutic Interventions

By enabling beneficial bacteria colonization in the gut, we believe our novel Activated Bacterial Therapeutic (ABT) delivery platform technology will revolutionize therapeutic interventions for diseases where there is erosion of the mucosal barrier.

Erosion of the physical mucus barrier leads to breaches and penetration of toxins, proteins and microbiota to enterocytes of the intestine. The result is collectively termed “leaky gut” and is often associated with low levels of chronic GI and systemic inflammation.

Enabling the delivery of active, live therapeutic bacteria capable of persisting in the gut and primed for adhesion to intestinal mucosa using our ABT technology will serve several unmet medical needs when applied as an intervention to fortify the mucosal barrier in states where breaches are documented.

Therapeutic Interventions